CHRS Stock Analysis: Buy, Sell, or Hold?
CHRS - Coherus Oncology, Inc. Common Stock
$1.73
-0.01 (-0.57%)
▼
5d:
+4.22%
30d:
-1.7%
90d:
+21.83%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 11, 2026
Smart Money Accumulation
CHRS is down 4.8% this week, but smart money is accumulating calls. Top strike: $2 2026-05-15 with 2,637 OI. Call ratio: 100% View Scanner →
Strength: 7.4/10
Get Alerted When CHRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CHRS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: CHRS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: CHRS is currently trading at $1.73, which is considered fair relative to its 30-day fair value range of $1.60 to $1.79.
Technical Outlook: Technically, CHRS is in a strong uptrend. Immediate support is located at $1.52, while resistance sits at $1.85.
Market Sentiment: CHRS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $6.75 (+290.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CHRS is in a strong uptrend. Immediate support is located at $1.52, while resistance sits at $1.85.
Market Sentiment: CHRS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $6.75 (+290.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$1.60 -
$1.79
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 290.2% below Wall St target ($6.75)
Fair Price Analysis
30-Day Fair Range
$1.60 -
$1.79
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$0.21
(12.3%)
Support & Resistance Levels
Support Level
$1.52
Resistance Level
$1.85
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.14
Wall Street Target
$6.75
(+290.2%)
Revenue Growth (YoY)
64.9%
Earnings Growth (YoY)
-75.5%
Profit Margin
398.4%
Share & Embed Analysis
Last updated: April 03, 2026 2:00 AM ET
Data refreshes hourly during market hours. Next update: 3:00 AM
Data refreshes hourly during market hours. Next update: 3:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CHRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
12 analysts |
$138 | 61 BUY |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 50 HOLD |
